Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 1Phase 1 1

Status

Terminated 6Active not recruiting 2Recruiting 1Completed 1

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 6

Sponsor

Cancer Type

Thoracic 6Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Neoplasm Metastasis 2Lung Neoplasms 1Carcinoma 1

Interventions

Carboplatin 158Pemetrexed 135Cisplatin 115pembrolizumab 99Docetaxel 94Paclitaxel 89Gemcitabine 63Erlotinib Hydrochloride 60Radiotherapy 55Nivolumab 55Bevacizumab 46Etoposide 42atezolizumab 33Radiosurgery 33durvalumab 28Cyclophosphamide 22Vinorelbine 21Ipilimumab 21Radiation 20Taxes 17130-nm albumin-bound paclitaxel 17Albumin-Bound Paclitaxel 16Gefitinib 14Irinotecan 13Drug Therapy 13osimertinib 12avelumab 12Magnetic Resonance Spectroscopy 12Dexamethasone 12Cetuximab 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Terminated × canakinumab × Thoracic × Clear all
NCT03631199 2026-02-25

CANOPY-1

Novartis

Phase 3 Terminated
673 enrolled 38 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT03447769 2024-10-09

Canopy-A

Novartis

Phase 3 Terminated
1,382 enrolled 23 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03968419 2024-06-20

CANOPY-N

Novartis

Phase 2 Terminated
88 enrolled 21 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03626545 2023-08-21

CANOPY-2

Novartis

Phase 3 Terminated
245 enrolled 29 charts
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT05725343 2023-02-13

CANAL

Mario Negri Institute for Pharmacological Research

Phase 3 Terminated
350 enrolled
Thoracic

Lung Neoplasms

NCT03064854 2022-08-15

PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients

Novartis

Phase 1 Terminated
111 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡